Review on the use of Bacteriophages as a promising way of mitigating the crisis of Antimicrobial resistance

Review on the use of Bacteriophages as a promising way of mitigating the crisis of Antimicrobial resistance

Rekik Getahoun, Getahun Shawul, Kibeb Legesse and Asmelash Tassew*

Addis Ababa University, College of Veterinary Medicine and Agriculture , Department of Veterinary Microbiology, Immunology and Public health, P.O.Box: 34; Debre Zeit, Ethiopia

American Journal of Biotechnology and Bioinformatics

Antibiotic resistance is considered as a major threat to therapeutics in this era. This resistance has occurred due to various actions that neglect the ethical use of antimicrobials and antibiotics ending up in the abuse of these drugs in clinical, veterinary or agricultural practices. As the number of resistant pathogens increase, more drugs are being produced to cope with the situation and many research methodologies have been carried out in search of an alternative antimicrobial to assuage the threat of antimicrobial resistance. Consequently, phage therapy was discovered and considered effective as well as an alternative way to control the problem of antimicrobial and antibiotic resistance. Bacteriophages are viruses that infect and lyse bacteria. They are commonly referred to as “phage”. They are obligate intracellular parasites that multiply inside bacteria by making use of some or all of the host biosynthetic machinery. The nucleic acids of phages often contain unusual or modified bases, which protect phage nucleic acid from nucleases that break down host nucleic acids during phage infection. Depending upon the phage, the nucleic acid can be either DNA or RNA but not both. Due to their unique characteristics they are considered more effective than other alternatives. Previous trials in the use of bacteriophages have proved that phage as therapeutics have the ability to target bacteria of certain strains or species, without any harmful effect on the rest of the bacterial microflora. Moreover, bacterial antibiotic resistance is not a barrier for phage therapy and they are more effective when combined with antibiotics. This paper briefly reviews the use of phage therapy as an effective alternative to mitigate the global anti microbial resistance problem we are currently battling.

Keywords: Alternative therapy, Antibiotic resistance, Bacteriophage, Phage therapy

Free Full-text PDF

How to cite this article:
Rekik Getahoun et al., Review on the use of Bacteriophages as a promising way of mitigating the crisis of Antimicrobial resistance. American Journal of Biotechnology and Bioinformatics, 2017; 1:3. DOI: 10.28933/ajobb-2017-09-2803

1. Ackermann, H. W. (2001): Frequency of morphological phage descriptions. Arch. Virol, 146: 843-857.
2. Atad, I., Zvuloni, A., Loya, Y. and Rosenberg, E. (2012): Phage therapy of the white plague-like disease of Favia favus in the red sea. J Coral Reefs, 31: 665-670.
3. Benett, P. M. and Howe, T. G. (1998): “Bacterial and bacteriophage genetics,” In Topley and Wilson’s Microbiology and Microbial Infections, 2; 9th Edition, Collier, L., Balows, A., Sussman, M., ed. (London: Arnold), 231-294.
4. Black, L. and Peng, G. (2006): Mechanistic coupling of bacteriophage T4 DNA packaging to components of the replication dependent late transcription machinery. J Biol Chem, 281:25635-25643.
5. Carlet, J. (2015): Global overview of AMR. In: Carlet, J., Pham, G. ed. AMR control 2015: Overcoming global antibiotic resistance. United Kingdom: Probart, T. 5-10.
6. Carlton, R. (1999): Phage therapy: Past history and future prospects. Arch. Immunol. Ther. Exp., 5: 267-274.
7. Chhibber, S., Kaur, T. and Sandeep, K. (2013): Co-therapy using lytic bacteriophage and linezolid: Effective treatment in eliminating methicillin resistant Staphylococcus aureus (MRSA) from diabetic foot infections. PLoS one, 8: 56022.
8. Cirz, R. T., Chin, J. K. and Andes, D. R. (2005): Inhibition of mutation and combating the evolution of antibiotic resistance. PLoS Biology, 3(6): 176.
9. D’Hérelle, F. (1918): Technique de la recherché du microbe filtrant bactériophage (Bacteriophagum intestinale). C.R. Soc. Biol., 81: 1160-1162.
10. Doss, J., Culbertson, K., Hahn, D., Camacho, J. and Barekzi, N. (2017): A review of phage therapy against bacterial pathogens of aquatic and terrestrial organisms. Viruses, 9: 50.
11. Eisenstark, A. (1967): Bacteriophage techniques. In: Maramorosch, K., Koprowski, H. (eds.), methods in Virology, 1. Academic Press, New York, 449-525.
12. Endley, S., Lu, L. and Vega, E. (2003): Male specific coliphages as an additional fecal contamination indicator for screening fresh carrots. J Food Prot, 66: 88-93.
13. Fischetti, V., Nelson, D. and Schuch, R. (2006): Reinventing phage therapy. J Appl Microb, 98: 7-13.
14. Fluit, A. C., Visser, M. R. and Schmitz, F. J. (2001):Molecular detection of antimicrobial resistance. Clin. Microbiol. Rev., 14: 836-871.
15. Goodridge, L. D. (2010): Designing phage therapeutics. Curr. Pharm. Biotechnol., 11: 15-27.
16. Golkar, Z., Bagasra, O. and Pace, D. (2014): Bacteriophage therapy: A potential solution for the antibiotic resistance crisis. J Infect Dev Ctries, 8(2):129-136.
17. Hanlon, G. W. (2007): Bacteriophages: an appraisal of their role in the treatment of bacterial infections. J Antimicrob Agents, 30: 118-128.
18. Highfield, R. (2014): Beyond antibiotics. Newsweek, Retrieved from: Accessed: March 2, 2017.
19. Ho, K. (2001): Bacteriophage therapy for bacterial infections. Rekindling a memory. Perspect. Biol. Med., 44: 1-16.
20. Hyman, P. and Abedon, S. (2010): Bacteriophage host range and bacterial resistance. Adv. Appl. Microbiol., 70: 217-248.
21. Hupfeld, M. and Loessner, M. (2014): Gives a comprehensive overview of the current (therapeutic) research. Bacteriophages, 20: 591.
22. Kiros, A., Gashaw, T. and Teshale, A. (2016): Phage Therapy; A Review on the Biology and Therapeutic Application of Bacteriophage. ARC J Anim Vet Sci, 2: 15-25.
23. Kutateladze, M. and Adamia, R. (2010): Bacteriophages as potential new therapeutics to replace or supplement antibiotics. Trends. Biotechnol., 28: 591-595.
24. Kutter, E., De-Vos, D., Gvasalia, G., Alavidze, Z., Gogokhia, L. and Kuhl, S. (2010): Phage therapy in clinical practice: Treatment of human infections. Curr. Pharm. Biotechnol., 11: 69-86.
25. Li, X. and Nikadio, H. (2009): Efflux-mediated drug resistance in bacteria. Drugs, 69(12): 1555-1623.
26. Mandal, S., Roy, A., Ghosh, A., Hazra, T., Basak, B. and Franco, O. (2014): Challenges and future prospects of antibiotic therapy: from peptides to phages utilization. Front. Pharmacol., 5: 105.
27. Maree, C., Daum, R. and Boyle-Vavra, S. (2007): Community associated methicillin resistant Staphylococcus aureus isolates causing healthcare-associated infections. Emerg. Infect. Dis., 13(2): 236-242.
28. Mathur, M., Vidhani, S. and Mehndiratta, P. (2003): Bacteriophage therapy; an alternative to conventional antibiotics: National staphylococcal phage typing center, 51: 593-595.
29. Matsuzaki, S., Rashel, M., Uchiyama, J., Sakurai, S., Ujihara, T., Kuroda, M., Ikeuchi, M., Tani T., Fujieda, M., Wakiguchi, H. and Imai, S. (2005): Bacteriophage therapy: a revitalized therapy against bacterial infectious diseases. J Infect Chemother, 11: 211-219.
30. Merril, C., Biswas, B., Carlton, R., Jensen, N., Creed, G., Zullo, S. and Adhya, S. (1996): Long circulating bacteriophage as antibacterial agents. Proc. Natl. Acad. Sci., 93: 3188-3192.
31. Morris, G., Sulakvelidze, A. and Alavidze, Z. (2001): Antimicrobial Agents. Chemotherapy, 45: 649-659.
32. Nakai, T. and Park, S. (2002): Bacteriophage therapy of infectious disease in aquaculture. Res. Microbiol., 153: 13-18.
33. Ogbodo, S. O., Okeke, A. C. and Chukwura, E. F. (2011): Possible alternatives to reduce antibiotic resistance. Life. Sci. Med. Res., 1-10.
34. Pirisi, A. (2000): Phage therapy advantages over antibiotics. Lancet. Infect. Dis., 356(9239): 1418.
35. Poole, K. (2004): Efflux mediated multiresistance in Gram-negative bacteria. Clin. Microbiol. Infect., 10(1): 12-26.
36. Prasad, Y., Kumar, D. and Sharma, A. (2011): Lytic bacteriophages specific to flavobacterium columnare rescue catfish, Clarias batrachus (linn.) from columnaris disease. J. Environ. Biol, 32: 161-168.
37. Rahmani, R., Zarrini, G., Sheikhzadeh, F. and Aghamohammadzadeh, N. (2014): Effective phages as green antimicrobial agents against antibiotic-resistant hospital Escherichia coli. J Microbiol, 8(2): 17744.
38. Rahmani, R., Zarrini, G., Sheikhzadeh, F. and Aghamohammadzadeh, N. (2015): Effective phages as green antimicrobial agents against antibiotic-resistant hospital Escherichia coli. J. Microbiol, 8: 17744.
39. Richards, G. P. (2014): Bacteriophage remediation of bacterial pathogens in aquaculture: A review of the technology. Bacteriophage, 4: 975540.
40. Robicsek, A., Jacoby, G. and Hooper, D. (2006): The worldwide emergence of plasmid mediated quinolone resistance. Lancet. Infect. Dis., 6(10): 629¬-640.
41. Sankar, A., Carl, R. and Biswajit, B. (2014): Therapeutic and Prophylactic Applications of Bacteriophage Components in Modern Medicine. J Microbiol, 4: 1-13.
42. Shan, Y. (2015): Antimicrobial Resistance, a growing crisis. J Prim Health Care, 26: 18-24.
43. Smith, H. W. and Huggins, M. B. (1982): Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotic. J Gen Microbiol, 128: 307-318.
44. Smith, H. W. and Huggins, M. B. (1983): Effectiveness of phages in treating experimental Escherichia coli diarrhea in calves, piglets and lambs. J Gen Microbiol, 129: 2659-2675.
45. Smith, H. W., Huggins, M. B. and Shaw, K. M. (1987): Factors influencing the survival and multiplication of bacteriophage in calves and in their environment. J Gen Microbiol, 133: 1127-11235.
46. Sulakvelidze, A., Alavidze, Z. and Glenn, M. (2001): Bacteriophage Therapy. Antimicrob.Agents. Chemother., 45: 649-659.
47. Tan, L., Chan, K. and Lee, L. (2014): Application of bacteriophage in biocontrol of major food borne bacterial pathogens. J Mol Biol and Mol, 1: 9.
48. Viertel, T., Ritter, K. and Horz, H. (2014): Viruses versus bacteria novel approaches to phage therapy as a tool against multidrug-resistant pathogens. J Antimicrob Chemother, 69(9): 2326-2336.
49. Wall, S. K., Zhang, J. Y., Rostagno, M. H. and Ebner, P. D. (2010): Phage therapy to reduce preprocessing Salmonella infections in market weight swine. Appl. Environ. Microbiol., 76: 48-53.
50. Wang, I., Smith, D. and Young, R. (2000): The protein clocks of bacteriophage infections. Annu. Rev. Microbial., 54: 799-825.
51. Wang, Y., Barton, M., Elliott, L., Li, X., Abraham, S., O’Dea, M. and Munro, J. (2017): Bacteriophage therapy for the control of Vibrio harveyi in green lip abalone (Haliotis laevigata). Aquaculture, 473: 251-258.
52. Weber-Dabrowska, B., Mulczyk, M. and Gorski, A. (2000): Bacteriophage therapy of bacterial infections. Arch. Immunol. Ther. Exp., 48: 547-551.
53. WHO (1988): Criteria for medicinal drug promotion. Geneva: World Health Organization.
54. WHO (2015): Antimicrobial Resistance: Factsheet Number 194. Accessed: March 24, 2017.
55. Yosef, I., Kiro, R. and Molshanski-Mor, S. (2014): Different approaches for using bacteriophages against antibiotic-resistant bacteria. Bacteriophage, 4: 28491.
56. Zahra, M. and Abdollah, G. (2011): Modified phages. Nov. Antimicrob. Infect. Dis., 732-738.

Terms of Use/Privacy Policy/ Disclaimer/ Other Policies:
You agree that by using our site, you have read, understood, and agreed to be bound by all of our terms of use/privacy policy/ disclaimer/ other policies (click here for details)

CC BY 4.0
This work and its PDF file(s) are licensed under a Creative Commons Attribution 4.0 International License.